BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Merck KGaA Adopts Quris-AI’s Organ-On-Chip Platform for Preclinical Drug Safety Testing

by Andrii Buvailo, PhD  (contributor )   •   Jan. 9, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Merck KGaA has integrated Quris-AI’s Bio-AI platform into its drug development pipeline to evaluate small molecule drug candidates for safety before clinical trials. The collaboration builds on a two-year validation study, where Quris-AI demonstrated higher accuracy in predicting drug-induced liver injury (DILI) compared to traditional preclinical methods, with the potential to reduce reliance on animal testing.

#advertisement
AI in Drug Discovery Report 2025

See also: Beyond Animal Testing: Organ-on-a-Chip Companies Usher in a New Era for Drug Trials

According to Prof. Robert S. Langer, a Moderna Co-Founder and Former Chairman of the FDA Science Board, currently member of the Quris-AI Scientific Advisory Board, the platform is "uniquely positioned to address the FDA Modernization Acts 2.0 and now 3.0, which push to use AI, organ-on-chip, and other advanced technologies to replace antiquated animal testing."

This partnership follows an earlier expansion in September 2023, when Merck KGaA extended its collaboration with Quris after a successful preclinical study that identified liver toxicity risks with high accuracy.

In November 2024, Quris-AI acquired Nortis, a company known for its Kidney-on-Chip technology. Nortis’s platform has been used in the NIH’s “Tissue Chips in Space” program, which investigates kidney function in microgravity. By incorporating Quris-AI’s platform, the system now benefits from enhanced AI-driven safety predictions for kidney toxicity. The technology uses human-derived kidney tissue to simulate complex organ functions, such as filtration and electrolyte balance, offering insights beyond the reach of traditional animal models. So far, research has already shown its ability to detect nephrotoxic effects that animal testing missed.

Quris-AI’s platform combines machine learning, generative AI, and patient-on-chip systems to model human responses to drug candidates. The system integrates high-throughput 3D organ models, real-time monitoring of biomarkers, and genomic diversity derived from stem cells. By simulating interactions across multiple interconnected organ models, the platform generates datasets that inform predictive algorithms. These algorithms are continuously refined through new experimental data, enabling more accurate assessments of drug safety and efficacy while reducing reliance on animal testing.

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.